Patients with primary Sjögren disease and low vitamin A levels demonstrate a higher frequency of ocular surface damage ...

The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.

A celebrity's recent multiple sclerosis misdiagnosis highlights the complexities of medical liability and the error in ...

The Association of Rheumatology Professionals (ARP) has developed programming highlighting the perspectives of ...

HealthDay News — A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial ...

Ursodeoxycholic acid recommended as first-line therapy and to prevent recurrence after liver transplant for PBC.

This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) ...

The designation is based on phase 2 data demonstrating dose-dependent increases in total sleep time among children and adolescents, including those with comorbid neurodevelopmental disorders.

GV101 selectively inhibits ROCK2 to upregulate FXN mRNA and restore frataxin protein expression. The Food and Drug Administration (FDA) has granted Fast Track designation to GV101 for the treatment of ...

HealthDay News — Utah has become the first state to let an artificial intelligence (AI) program prescribe medication without a doctor writing the prescription, starting with acne treatments.

Results from the phase 3 VOCAL study demonstrate that oral vadadustat dosed 3 times per week successfully maintains hemoglobin levels vs standard ESA therapy in adult hemodialysis patients.